Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Papilloma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    100 result(s) found for: Papilloma. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-004524-65 Sponsor Protocol Number: Inf.Q002 Start Date*: 2015-11-30
    Sponsor Name:Department of Infectious Diseases
    Full Title: Efficacy of nonavalent vaccine against human papilloma virus (HPV ) in HIV infected sexually active men who have sex with men (MSM)
    Medical condition: The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    18.1 100000004865 10071147 Human papilloma virus immunization LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004654-19 Sponsor Protocol Number: 1526-IMIQ Start Date*: 2005-04-20
    Sponsor Name:3M ITALIA
    Full Title: Multicenter, randomized, double-blind, vehicle-controlled study comparing recurrence rate following imiquimod 5% cream or vehicle 3 times per week for 4 weeks prior to ablative therapy in subjects ...
    Medical condition: External ano-genital warts
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033724 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002667-14 Sponsor Protocol Number: UHKT-RLP/2011 Start Date*: 2011-07-19
    Sponsor Name:Institute of Hematology and Blood Transfusion
    Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?
    Medical condition: Recurrent respiratory papillomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023849 Laryngeal papilloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-003852-13 Sponsor Protocol Number: V504-001-00 Start Date*: 2007-11-09
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005717-23 Sponsor Protocol Number: V501-018-00 Start Date*: 2015-12-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age
    Medical condition: HPV
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000764-85 Sponsor Protocol Number: V501-024-00 Start Date*: 2006-05-10
    Sponsor Name:Merck & Co., Inc
    Full Title: A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age
    Medical condition: Prevention of Human Papillomavirus Infection
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001170-29 Sponsor Protocol Number: V503-066 Start Date*: 2024-02-05
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Open-label Clinical Study to Evaluate the Immunogenicity and Safety of 9vHPV Vaccine, in Japanese Boys and Girls, 9 to 15 Years of Age.
    Medical condition: Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-003736-24 Sponsor Protocol Number: V503-069 Start Date*: 2021-03-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005569-38 Sponsor Protocol Number: CLS003-CO-PR-001 Start Date*: 2014-02-17
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in...
    Medical condition: Cutaneous warts
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10033724 Papilloma viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016218-26 Sponsor Protocol Number: V503-007 Start Date*: 2010-03-15
    Sponsor Name:MSD Finland Oy
    Full Title: A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With R...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) Types 6, ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002193-23 Sponsor Protocol Number: HLS04/2011 Start Date*: 2011-09-27
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled cli...
    Medical condition: HIV+ teenagers and young adults versus HIV-negative subjects: high-risk population for HPV-related disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005229-26 Sponsor Protocol Number: RIFT-HPV Start Date*: 2022-03-09
    Sponsor Name:Dr. Miguel Angel Pavón Ribas
    Full Title: A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women Before and After Vaccination with 9vHPV, a Mul...
    Medical condition: Human Papillomavirus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005093-38 Sponsor Protocol Number: V503-004 Start Date*: 2016-07-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27-...
    Medical condition: Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061331 Papilloma viral infection PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed) AT (Completed) ES (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000518-37 Sponsor Protocol Number: 580299/013 Start Date*: 2004-08-27
    Sponsor Name:GlaxoSmithKline AS
    Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered intramuscularly according t...
    Medical condition: cervical cancer: the study is conducted in healthy female adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: NO (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000757-22 Sponsor Protocol Number: 114700 Start Date*: 2011-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscu...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA